The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
The CATIE program was initiated by the National Institute of Mental Health, and involves 50 collaborating clinical sites across the United States. The main goal of CATIE is to evaluate the effectiveness of antipsychotic drugs (olanzapine, quetiapine, risperidone, ziprasidone, perphenazine), particularly within common settings and populations to increase the generalizability of findings. The program is designed to follow 1,500 patients with schizophrenia over at least 18 months to collect information on all-cause treatment discontinuation (primary outcome), and symptoms, side effects, neurocognitive functioning, and cost-effectiveness (secondary outcomes). For more information on the CATIE program, please refer to Stroup et al., 2003
Our research here has also involved re-analysis of the genome-wide association study data from CATIE to identify new variants associated with AIWG. For more details on some of our recent projects, see Brandl et al., 2015
more information on CATIE trial, please refer to this publication.